Cybin (CYBN) Company Overview

The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin's multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major De.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, and Amir Inamdar, MBBS, DNB (Psych), FFPM, Cybin's Chief Medical Officer, will participate in the Water Tower Research Fireside Chat Series taking place.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phene.

Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and provider convenience. Cybin's trial results, robust IP portfolio, and solid financials de-risk its path to FDA approval, with a market cap significantly lower than competitors.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET. The fireside chat will be ho.

Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”. Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”.